Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on trastuzumab benefits come from clinical trials, conducted...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Vici, Patrizia, Pizzuti, Laura, Natoli, Clara, Moscetti, Luca, Mentuccia, Lucia, Vaccaro, Angela, Sergi, Domenico, Di Lauro, Luigi, Trenta, Patrizia, Seminara, Patrizia, Santini, Daniele, Iezzi, Laura, Tinari, Nicola, Bertolini, Ilaria, Sini, Valentina, Mottolese, Marcella, Giannarelli, Diana, Giotta, Francesco, Maugeri-Saccà, Marcello, Barba, Maddalena, Marchetti, Paolo, Michelotti, Andrea, Sperduti, Isabella, Gamucci, Teresa
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2014
Schlagworte:
Clinical Trial
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4174332/
https://ncbi.nlm.nih.gov/pubmed/25234842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3133-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge